Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pembrolizumab in Patients With Cutaneous or, Subcutaneous Lesions or Easily Injectable Lymph Nodes of Metastatic/Advanced Solid Tumors.

NCT04725331 is registered in ClinicalTrials.gov with Transgene as lead sponsor.

NCT NCT04725331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04725331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pembrolizumab in Patients With Cutaneous or, Subcutaneous Lesions or Easily Injectable Lymph Nodes of Metastatic/Advanced Solid Tumors.
Lead sponsor
Transgene
Phase
Phase 1/2
Overall status
Terminated
Start date
February 25, 2021
Completion date
October 22, 2025
Enrollment
31 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, merkel cell carcinoma, metastatic cancer, non small cell lung cancer, soft tissue sarcoma, triple negative breast cancer